Abstract
Serological evaluation for neuromuscular disorders expands commensurate with understanding of their autoimmune etiology. In myasthenia gravis (MG) and Lambert-Eaton syndrome (LES) and stiff person syndrome (SPS), there is a clear link between an autoantibody and disease pathogenesis, while the association of autoantibodies and inflammatory myopathies is less clear. Despite the uncertainty of the pathogenic role of autoantibodies in certain disorders, their detection may be useful in diagnosis and prognosis. This chapter reviews use of serological evaluation in diagnosis of neuromuscular junction disorders, hyperexcitability syndromes, and inflammatory muscle diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity. 2010;43:371–9.
Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:973808.
Trakas N, Zisimopoulou P, Tzartos SJ. Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis. J Neuroimmunol. 2011;240–241:79–86.
Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol. 2010;23:530–5.
Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol. 2005;62:1002–3.
Hanisch F, Eger K, Zierz S. MuSK-antibody positive pure ocular myasthenia gravis. J Neurol. 2006;253:659–60.
Lennon V. Serologic profile of myasthenia gravis and distinction from Lambert-Eaton myasthenic syndrome. Neurology. 1997;48 Suppl 5Suppl 5:S23–7.
Limburg PC, The TC, Hummel-Teppel E, Oosterhuis H. Anti-acetylcholine receptor antibodies in myasthenia gravis. I. Relation to clinical parameters in 250 patients. J Neurol Sci. 1983;58:357–70.
Howard FJ, Lennon V, Finley J, Matsumoto J, Elveback L. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526–38.
Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36:651–8.
Yang L, Maxwell S, Leite MI, et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J Neurol Sci. 2011;301:71–6.
Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008;131:1940–52.
Lindstrom JM, Seybold MD, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054–9.
Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29:484–505.
Sundewall AC, Lefvert AK, Olsson R. Anti-acetylcholine receptor antibodies in primary biliary cirrhosis. Acta Med Scand. 1985;217:519–25.
Pascuzzi RM, Phillips 2nd LH, Johns TR, Lennon VA. The prevalence of electrophysiological and immunological abnormalities in asymptomatic relatives of patients with myasthenia gravis. Ann N Y Acad Sci. 1987;505:407–15.
Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci. 2008;1132:220–4.
Kaminski H, Zhou Y, Soltys J, Kusner L. The complement hypothesis to explain preferential involvement of extraocular muscle by myasthenia gravis. In: Leigh R, Devereaux M, editors. Advances in understanding mechanisms and treatment of infantile forms of nystagmus. New York: Oxford University Press; 2008.
MacLennan C, Beeson D, Buijs A-M, Vincent A, Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol. 1997;41:423–31.
Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57:444–8.
Lanska DJ. Diagnosis of thymoma in myasthenics using anti-striated muscle antibodies: predictive value and gain in diagnostic certainty. Neurology. 1991;41:520–4.
Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011;2011:740583.
Gautel M, Lakey A, Barlow D, et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology. 1993;43:1581–5.
Mygland A, Tysnes O-B, Matre R, Volpe P, Aarli J, Gilhus N. Ryanodine receptor autoantibodies in myasthenia gravis patients with thymoma. Ann Neurol. 1992;32:589–91.
Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol. 2000;247:369–75.
Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. 2005;62:442–6.
Cikes N, Momoi M, Williams C, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma and recipients of D-penicillamine and allogenic bone marrow. Mayo Clin Proc. 1988;63:474–81.
Skeie GO, Mygland Å, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity. 1995;20:99–104.
Mygland A, Aarli J, Matre R, Gilhus N. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994;57:843–6.
Mygland Å, Vincent A, Newsom-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000;57:527–31.
Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol. 2000;57:1596–600.
Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–74.
Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85–7.
Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev. 2003;2:94–100.
Martin-Moutot N, De Haro L, Seagar M. Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2008;197:47–53.
Vernino S, Sandroni P, Singer W, Low PA. Invited article: autonomic ganglia: target and novel therapeutic tool. Neurology. 2008;70:1926–32.
Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA. Neuronal nicotinic AChR antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998;50:1806–13.
Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26:702–7.
Lennon V. Serological diagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. In: Dekker M, editor. Handbook of myasthenia gravis and myasthenic syndromes. New York: Marcel Dekker; 1994. p. 149–64.
Lennon V, Lambert E, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1982;5:S21–5.
Lamb GD. Rippling muscle disease may be caused by “silent” action potentials in the tubular system of skeletal muscle fibers. Muscle Nerve. 2005;31:652–8.
Liewluck T. Immune-mediated rippling muscle disease: another inflammatory myopathy in myasthenia gravis. Arch Neurol. 2010;67:896–7.
Loukaides P, Schiza N, Pettingill P, et al. Morvan’s syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. J Neurol Sci. 2012;312:52–6.
Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci. 2003;998:202–10.
Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995;38:714–22.
Hart I, Water C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol. 1997;41:238–46.
Arimura K, Sonoda Y, Watanabe O. Isaacs’ syndrome as a potassium channelopathy of the nerve. Muscle Nerve. 2002;1 Suppl 1Suppl 1:S55–8.
Helfgott SM. Stiff-man syndrome: from the bedside to the bench. Arthritis Rheum. 1999;42:1312–20.
Murinson BB, Butler M, Marfurt K, Gleason S, De Camilli P, Solimena M. Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology. 2004;63:2146–8.
Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol. 1998;44:194–201.
Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. 2001;57:780–4.
Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347:151–6.
Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med. 1990;322:1555–60.
Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71:1955–8.
Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol. 2011;24:346–53.
Sommer C, Weishaupt A, Brinkhoff J, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005;365:1406–11.
Evoli A. Antibody-phenotype correlation in stiff-person syndrome. Neurology. 2008;71:1938–9.
Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58:96–107.
Plotz P, Rider LG, Targoff IN, Raben N, Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122:715–24.
Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–12.
Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–54.
Miller FW. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am. 1994;20:811–26.
Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am. 1992;18:455–82.
Hirakata M, Suwa A, Takeda Y, et al. Autoantibodies to glycyl-transfer RNA synthetase in myositis. Association with dermatomyositis and immunologic heterogeneity. Arthritis Rheum. 1996;39:146–51.
Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009;80:1060–8.
Hirakata M. Autoantibodies to aminoacyl-tRNA synthetases. Intern Med. 2005;44:527–8.
Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008;10:333–40.
Koffman B, Rugiero M, Dalakas M. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve. 1998;21:115–77.
Hengstman G, van Engelen B, Badrising U, van den Hoogen F, van Venrooij W. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis (letter). Ann Neurol. 1998;44:423.
Hengstman GJ, van Brenk L, Vree Egberts WT, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol. 2005;252:534–7.
Love L, Leff R, Fraser D, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70:360–74.
Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA. 2011;305:183–90.
Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002;73:420–8.
Ghirardello A, Zampieri S, Iaccarino L, et al. Anti-Mi-2 antibodies. Autoimmunity. 2005;38:79–83.
Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28:796–803.
Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–9.
Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006;8:196–203.
Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology. 2007;46:25–8.
Joffe M, Love L, Leff R. Drug therapy of idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–87.
Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003;16:569–75.
Ioannou Y, Sultan S, Isenberg D. Myositis overlap syndromes. Curr Opin Rheumatol. 1999;11:468–74.
Garton M, Isenberg D. Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases. Br J Rheumatol. 1997;36:1067–74.
Arad-Dann H, Isenberg D, Ovadia E, Shoenfeld Y, Sperling J, Sperling R. Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. J Autoimmun. 1989;2:877–88.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bayat, E., Kaminski, H.J. (2014). Autoantibody Testing of Autoimmune Neuromuscular Junction, Hyperexcitability, and Muscle Disorders. In: Katirji, B., Kaminski, H., Ruff, R. (eds) Neuromuscular Disorders in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6567-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6567-6_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6566-9
Online ISBN: 978-1-4614-6567-6
eBook Packages: MedicineMedicine (R0)